P.2.043 Treatment of acutely exacerbated including highly agitated schizophrenic patients with oral risperidone

Background: This study evaluates and compares how negative and positive symptoms of schizophrenia were influenced with monotherapy with a first-generation anti-psychotic medication (Chlorpromazine) and a second generation anti-psychotic medication (Risperidone) and by their combination, both of which are commonly used in clinical psychiatric practice.Methods: It was randomized, double-blind, controlled clinical study performed in Indian newly diagnosed schizophrenic patients in the Department of psychiatry from Feb 2003 to March 2004. Patients 18 (eighteen) patients aged 20 to 60 years diagnosed schizophrenics according to ICD-10 Criteria who visited in outpatient department of psychiatry during study period. Three groups of 6 Patient each, group-1 - was treated with oral Chlorpromazine 100 mg 12 hly, group -2 - was treated with oral Risperidone 2mg 12 hly group 3 -was treated with combination of oral Chlorpromazine 100mg 12 hly + oral Risperidone 2 mg 12 hly. How symptomatology in schizophrenic patients affected, is measured by applying various validated psychiatric scales like Brief psychiatric Rating Score (BPRS), Scale for assessment of positive symptom(SAPS), and Scale for Assessment of Negative Symptoms (SANS).Results: the study showed that the combination therapy of oral Chlorpromazine 100 mg 12 hly + Risperidone 2mg 12 hly had reduced the overall beneficial effects which were achieved with monotherapy of both the drugs.Conclusions: In this study, the therapeutic effects of combination of oral Chlorpromazine 100 mg 12 hly + Risperidone 2 mg 12 hly found to be reduced on positive symptoms and negative symptoms of schizophrenia, assessed on SAPS and SANS scoring scales when compared with beneficial effects which were achieved with monotherapy of both the drugs.

Download Full-text

Weight Gain and Hyperprolactinemia in Schizophrenic Patients Treated During Twelve Months with Long Acting Risperidone

European Psychiatry ◽

10.1016/s0924-9338(09)71237-4 ◽

2009 ◽

Vol 24 (S1) ◽

pp. 1-1 ◽

Cited By ~ 1

Author(s):

F. Duarte Garcia ◽

F. Duval ◽

F. Gonzales Lopera ◽

M.-C. Mokrani ◽

Y. Hode ◽

...

Keyword(s):

Body Weight ◽

Weight Gain ◽

Food Intake ◽

Oral Risperidone ◽

Significant Weight Gain ◽

Length Of Treatment ◽

Schizophrenic Patients ◽

Long Acting ◽

Risperidone Treatment

Background:Risperidone (RISP) may induce both elevated prolactin (PRL) levels and weight gain. the aim of this study was to evaluate body weight and mass index (BMI), and PRL modifications in schizophrenic patients treated for 1 year with long-acting risperidone (LAR).Methods:Body weight and BMI (calculated as weight in kilograms divide by height in meter squared) were determined at baseline and at endpoint in 19 schizophrenic patients (9 men and 10 women; mean[SEM] age 33.4[2.9] years). PRL levels were determined at baseline, after oral risperidone treatment (mean length of treatment: 79[30] days; mean dose: 5.8[0.5] mg daily) and during a 12 month treatment with LAR (mean dose: 50[10] mg every 2 weeks; PRL levels were measured before each injection).Results:At endpoint, a significant weight gain (Δweight: 8,1[1,4] kg) and BMI (ΔBMI: 2,9[0,5] kg/m²) was observed (both p< 0.0002). Compared with baseline, PRL levels were significantly increased (p< 0.0007; mean ΔPRL: 33[8] ng/ml). There was an association between ΔBMI>1,5 kg/m² and ΔPRL>40 ng/ ml (p< 0.04). Moreover ΔBMI was linked to the length of treatment (rho=0.47; n=19; p< 0.05).Conclusions:Our results suggest a link between weight gain and long term hyperprolactinemia in patients treated with LAR. It has been hypothesized that PRL may have a role in the regulation of food intake by increasing leptin synthesis and secretion.

Download Full-text

Adjuvant role of testosterone in treatment of schizophrenia and its interaction with combination of first and second generation anti-psychotics, chlorpromazine and risperidone

International Journal of Basic & Clinical Pharmacology ◽

10.18203/2319-2003.ijbcp20182422 ◽

2018 ◽

Vol 7 (7) ◽

pp. 1247

Author(s):

Tarun Vijaywargia

Keyword(s):

Single Dose ◽

Negative Symptoms ◽

Second Generation ◽

Positive Symptom ◽

Anti Psychotic ◽

Double Blind ◽

Oral Risperidone ◽

Schizophrenic Patients ◽

First And Second Generation

Background: There is great controversy about role of male sex steroid, testosterone, in mental disorders like schizophrenia. This study assessed the effectiveness of testosterone in schizophrenic patients and probes how it modulates the action of combination of first and second generation anti-psychotic medications (Chlorpromazine + Risperidone) both of which are very commonly used anti-psychotic agents in clinical psychiatric practice.Methods: It Is randomized, double-blind, Clinical study performed in Indian schizophrenic patients (new cases) in the Department of psychiatry from Feb 2003 to March 2004. Patients twelve (12) patients aged 20 to 60 years diagnosed schizophrenics according to ICD-10 Criteria who visited in outpatient department of psychiatry during study period. 12 Patient was treated with combination of oral Chlorpromazine 200mg BD + oral Risperidone 2mg BD, half of the 12 patients also received single dose of testosterone 100mg intramuscularly with above-mentioned treatment. Measure How symptomatology in schizophrenic patients affected is measured by applying various validated psychiatric scales like Brief psychiatric Rating Score (BPRS), Scale for assessment of positive symptom(SAPS), and Scale for Assessment of Negative Symptoms (SANS).Results: Single dose of Testosterone 100mg administered initially by I.M. route potentiated the reduction level in negative symptoms of schizophrenia by 119% in patients receiving oral Chlorpromazine 200mg along with oral Risperidone 4mg/day.Conclusions: In this study, Testosterone potentiated the effects of combination of oral Chlorpromazine 100mg BD + Risperidone 2mg BD, on general psychotic manifestations, positive symptoms and negative symptoms of schizophrenia, assessed on BPRS, SAPS and SANS scoring scales, however the effect is most pronounced in negative symptomology of schizophrenia.

Download Full-text

Brain electric microstates in schizophrenic patients display deviant adaptation of the functional brain state

Electroencephalography and Clinical Neurophysiology ◽

10.1016/s0013-4694(97)88377-4 ◽

1997 ◽

Vol 103 (1) ◽

pp. 92

Author(s):

T Koenig

Keyword(s):

Brain State ◽

Functional Brain ◽

Schizophrenic Patients

Download Full-text

The self and schizophrenia: a cognitive approach

Swiss Journal of Psychology ◽

10.1024//1421-0185.62.1.45 ◽

2003 ◽

Vol 62 (1) ◽

pp. 45-51 ◽

Cited By ~ 5

Author(s):

Marek Nieznanski

Keyword(s):

Normal Subjects ◽

Control Group ◽

Cognitive Approach ◽

Schizophrenic Patients ◽

Self Schema ◽

Persons With Schizophrenia ◽

Basic Features ◽

Trait Words ◽

Patients Experience ◽

Normal Controls

The aim of the study was to explore the basic features of self-schema in persons with schizophrenia. Thirty two schizophrenic patients and 32 normal controls were asked to select personality trait words from a check-list that described themselves, themselves as they were five years ago, and what most people are like. Compared with the control group, participants from the experimental group chose significantly more adjectives that were common to descriptions of self and others, and significantly less that were common to self and past-self descriptions. These results suggest that schizophrenic patients experience their personality as changing over time much more than do healthy subjects. Moreover, their self-representation seems to be less differentiated from others-representation and less clearly defined than in normal subjects.

Download Full-text

An ERP Investigation of Semantic Priming, Repetition Priming, and Negative Priming in Schizophrenic Patients

Journal of Psychophysiology ◽

10.1027/0269-8803.20.3.195 ◽

2006 ◽

Vol 20 (3) ◽

pp. 195-211 ◽

Cited By ~ 7

Author(s):

Michael Wagner ◽

Lioba Baving ◽

Patrick Berg ◽

Rudolf Cohen ◽

Brigitte Rockstroh

Keyword(s):

Negative Priming ◽

Repetition Priming ◽

Event Related Potentials ◽

Decision Task ◽

Positive Priming ◽

Retrieval Processes ◽

Schizophrenic Patients ◽

Related Potentials ◽

Late Positive Complex ◽

Automatic Memory

The processing of attended and nonattended stimuli in schizophrenic patients was examined with event-related potentials (ERPs) in a lexical decision task. In positive semantic and repetition priming the N400 amplitude did not differ between a group of 17 medicated schizophrenic patients and a group of 20 matched healthy controls. However, negative priming affected the N400 only in controls. Reaction time effects were dissociated from these ERP effects, with patients showing stronger positive priming than controls but identical negative priming. The semantic processes related to the N400 appear to be intact in schizophrenic patients, but patients seem to incorporate less context information (about the nonattended prime) in their episodic memory traces. A stronger increase of the posterior late positive complex in parallel to the stronger positive priming in schizophrenic patients may reflect relatively stronger automatic memory retrieval processes in patients.

Download Full-text

The Antiaggressive Action of Combined Haloperidol-Propranolol Treatment in Schizophrenia

European Psychologist ◽

10.1027//1016-9040.5.4.312 ◽

2000 ◽

Vol 5 (4) ◽

pp. 312-325 ◽

Cited By ~ 9

Author(s):

Gadi Maoz ◽

Daniel Stein ◽

Sorin Meged ◽

Larisa Kurzman ◽

Joseph Levine ◽

...

Keyword(s):

Rating Scales ◽

Double Blind ◽

Propranolol Group ◽

Schizophrenic Patients ◽

Propranolol Treatment ◽

Simultaneous Decrease ◽

The Mean ◽

Haloperidol Treatment ◽

To Receive ◽

Drug Free

Psychopharmacological interventions for managing aggression in schizophrenia have thus far yielded inconsistent results. This study evaluates the antiaggressive efficacy of combined haloperidol-propranolol treatment. Thirty-four newly admitted schizophrenic patients were studied in a controlled double-blind trial. Following a 3-day drug-free period and 7 days of haloperidol treatment, patients were randomly assigned to receive either haloperidol-propranolol or haloperidol-placebo for eight consecutive weeks. Doses of medications were adjusted as necessary; biperiden was administered if required. Rating scales were applied to assess aggression, anger, psychosis, depression, anxiety and extrapyramidal symptoms. The mean daily dose of haloperidol was 21 mg (SD = 6.4) in the research group and 29 mg (SD = 6.9) in the controls. Mean and maximal daily doses of propranolol were 159 mg (SD = 61) and 192 mg (SD = 83), and of placebo, 145 mg (SD = 50) and 180 mg (SD = 70), respectively. Compared with the controls, the scores for the research patients decreased significantly from baseline, particularly after 4 weeks of treatment, for some dimensions of anger, psychosis, anxiety, and neuroleptic-induced parkinsonism. A tendency for reduced aggression was shown in the combined haloperidol-propranolol group for some dimensions but not others. These patients also required significantly less biperiden. The tendency toward elevated antiaggressive effect of combined haloperidol-propranolol treatment compared to haloperidol alone may be explained by a simultaneous decrease in aggression, psychotic symptomatology, and anxiety.

Download Full-text